Clinical Trial Search

Primary: Overall Survival — 89.2 percentage of participants

Primary: Patient Health Questionnaire (PHQ-9); Change in Depression Scores Taken at 4-, 8-, and 12-month Follow Ups as Compared to Baseline. — 16.40; 16.34; 11.74; 14.94 score on…

Primary: Change From Baseline in HbA1c at Week 26 Comparing Sotagliflozin 400 mg Versus Placebo — -0.11; -0.40 percentage of HbA1c — p=0.0962

Primary: Proportion of Days Covered (PDC) — 82.6; 75.6; 78.4; 73.3 percentage of days covered

Primary: Rate of Severe Toxicity — 14; 75; 43 Participants

Primary: The Number of Patients With First Dose Successful Termination of the Supraventricular Tachycardia to a Sinus Rhythm of Less Than 140 With the AHA Versus a Simplified…

Primary: Number of Participants With Adverse Events (AEs): Phase I & II — 13; 13; 5; 11 Participants

Primary: Intensive Study: Overall Survival (OS) — 17.3; 20.4 months — p=0.6579

Primary: Change in FEV1 Percentage Predicted From Baseline — 11.8; 8.8 percentage of predicted

Primary: Mechanical Ventilation — 2; 7 Participants

Primary: Change in Cerebral Blood Flow as Measured With Arterial Spin Labeling — 31.7; 26.9; 30.0; 25.0 cc/100 mg/min

Primary: Number of Participants With Smoking Cessation — 60; 44 Participants — p=0.0051

Primary: Occipital-frontal Head Circumference During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age — 38.7; 38.7 cm

Primary: Clinical and Radiological Complete Clinical Response (crCR) Rate at 3 Months — 9; 8; 4 participants

Primary: Treatment-Emergent Adverse Event Frequency by Treatment - Number of Patients Reporting Events — 10; 8; 14; 10 Participants